APA (7th ed.) Citation

VB, T., E, R., C, N., I, E., J, K., UM, B., . . . F, C. (2025). Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA). Wellcome open research, 10, 166. https://doi.org/10.12688/wellcomeopenres.23363.1

Chicago Style (17th ed.) Citation

VB, Tumusiime, et al. "Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA)." Wellcome Open Research 10 (2025): 166. https://doi.org/10.12688/wellcomeopenres.23363.1.

MLA (9th ed.) Citation

VB, Tumusiime, et al. "Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA)." Wellcome Open Research, vol. 10, 2025, p. 166, https://doi.org/10.12688/wellcomeopenres.23363.1.